Loading
A phase 3 trial testing ZG006 in non-small-cell lung cancer, now recruiting.
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07189455, led by Suzhou Zelgen Biopharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer. Planned enrolment is 420 participants (estimated). The study started in 2025-12-12 and primary completion is expected in 2028-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares Suzhou Zelgen Biopharmaceuticals, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/